GDF15 has been identified as a criticalmediator of CINV; elevated circulating GDF15 concentrations correlatewith cachexia and reduced survival in patients diagnosed with cancer.34,35 Importantly, none of the current FDA-approved antiemetics used inthe oncology field successfully counteracted GDF15-induced anorexiaand malaise in rats,32 suggesting thatGDF15 may account for the lack of complete CINV control in patients,thus stressing the importance of developing additional treatmentsto effectively block GDF15 effects. Here, GDF15 is linked to cancer.